Shionogi & Co., Ltd. (SGIOF)

49,60 0,00 (0,00%) Alla chiusura: 09:38AM EDT

Shionogi & Co., Ltd.

1-8, Doshomachi 3-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6202 2161
https://www.shionogi.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5.680

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Isao Teshirogi Ph.D.	CEO, President & Representative Director	1,86M	N/D	1959
Susumu Mitsumori	Vice President of Finance & Accounting Department	N/D	N/D	N/D
Mr. Kazuhiro Hatanaka	Senior Executive Officer & Senior VP of Administration Division	N/D	N/D	N/D
Mr. Takeshi Shiota Ph.D.	Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.	N/D	N/D	N/D
Mr. Yoshimasa Kyokawa	Vice President of Corporate Communications & Secretary Office	N/D	N/D	N/D
Yoshihiro Furuya	Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office	N/D	N/D	N/D
Mr. Kohji Hanasaki Ph.D.	Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division	N/D	N/D	N/D
Dr. John A. Keller Ph.D.	Senior Executive Officer and Senior VP of R&D Supervisory Unit	N/D	N/D	1965
Akira Kato Ph.D.	Corporate Officer & President of Shionogi Pharma Co., Ltd	N/D	N/D	N/D
Dr. Ryuichi Kiyama Ph.D.	Senior Executive Officer & Senior VP of Corporate Strategy Division	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Governance aziendale

L'ISS Governance QualityScore di Shionogi & Co., Ltd. al 29 aprile 2024 è 1. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 1; diritti degli azionisti: 3; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.